Cronos Group Inc.

Cronos Group Inc., (NASDAQ: CRON) a global cannabinoid company, has reported an increase in net revenue for the first quarter of 2024. The company's net revenue surged by 30%, reaching $25.3 million, driven primarily by sales in Canada and Israel. Despite this revenue upswing, Cronos posted a...

US legal cannabis sales are predicted to exceed $28 billion in 2023, with promising regulatory developments such as the recommendation to "reschedule" cannabis by the HHS. Canada's cannabis exports have surged to C$160 million, a 50% increase year-on-year, and with new international...

In an exclusive preview from Zuanic & Associates' recent cannabis equity research report, Benzinga reveals four key predictions for the next 18 months. The SAFE Banking bill is expected to pass in the fall of 2024. Key Senate players will aim for a "midpoint" compromise on add-...

Cronos Touts Uptick In Revenue, Appoints New CEO Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) revealed Thursday its consolidated net revenue for the third quarter amounted to approximately $11.4 million. That's up by $5.6 million or 96% on a yearly basis. For the nine months ended Sept. 30, net...